Revelation Biosciences Inc expected to post a loss of $1.33 a share - Earnings Preview

Reuters11-04

<a href="https://laohu8.com/S/REVBU">Revelation Biosciences</a> Inc <revb.oq> expected to post a loss of $1.33 a share - Earnings Preview </revb.oq>

Revelation Biosciences Inc REVB.OQ REVB.O is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Revelation Biosciences Inc is for a loss of $1.33 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Revelation Biosciences Inc is $21.25, about 94.4% above its last closing price of $1.20

This summary was machine generated November 4 at 11:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580780349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580780349","market":"us","top_or_hot":-1,"title":"Revelation Biosciences Inc  expected to post a loss of $1.33 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> Inc <revb.oq> expected to post a loss of $1.33 a share - Earnings Preview </revb.oq></title></head><body><ul><li><p><a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc <span>REVB.OQ</span> <span>REVB.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a> Inc is for a loss of $1.33 per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Revelation Biosciences Inc is $21.25, about 94.4% above its last closing price of $1.20</p></li></ul><p>This summary was machine generated November 4 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revelation Biosciences Inc  expected to post a loss of $1.33 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevelation Biosciences Inc  expected to post a loss of $1.33 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> Inc <revb.oq> expected to post a loss of $1.33 a share - Earnings Preview </revb.oq></title></head><body><ul><li><p><a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc <span>REVB.OQ</span> <span>REVB.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a> Inc is for a loss of $1.33 per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Revelation Biosciences Inc is $21.25, about 94.4% above its last closing price of $1.20</p></li></ul><p>This summary was machine generated November 4 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REVB","symbol_name":"Revelation Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG13S:1","article_id":"2580780349","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580780349","pubTimestamp":1762255384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revelation Biosciences Inc  expected to post a loss of $1.33 a share - Earnings Preview Revelation Biosciences Inc REVB.OQ REVB.O is expected to  show no change in quarterly revenue when it reports  r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REVB":"Revelation Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Revelation Biosciences Inc预计每股亏损1.33美元-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REVB":0.9},"content_text":"Revelation Biosciences Inc  expected to post a loss of $1.33 a share - Earnings Preview Revelation Biosciences Inc REVB.OQ REVB.O is expected to  show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2025LSEG's mean analyst estimate for Revelation Biosciences Inc is for a loss of $1.33 per share. The one available analyst rating on the shares is \"buy\".  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Revelation Biosciences Inc is $21.25, about 94.4% above its last closing price of $1.20This summary was machine generated November 4 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580780349","isCrawlerRequest":true}